skint, page-2

Yeah, management need a good whipping as far as I'm concerned. Announcement dated 29th November 2006 (14 weeks ago):

Solbec, along with its independent toxicologist and specialist regulatory advisers are preparing a development plan for submission to the TGA
which it anticipates lodging within 3-4 weeks.

Nothing has been announced since about this critical issue. Furthermore, the MD resigned for personal reasons last year and no announcement has been made regarding a replacement, which means for the last few months, no one has been in charge. How can one of the most promising biotech companies in Australia, with Orphan Drug status awarded TWICE for two different cancer lines, be valued at less than $10mil..?